Novavax has shared prelim efficacy data by press release:
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
90% overall, 50% in S Africa (60%) in HIV-.
But there's more...
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
90% overall, 50% in S Africa (60%) in HIV-.
But there's more...
@carlzimmer has written a nice story about it here:
https://twitter.com/carlzimmer/status/1354898936482455553
Article makes very provocative statement - that previous exposure doesn't protect against new variant B.1.351 found initially in S africa. But where are data to support this?
https://twitter.com/carlzimmer/status/1354898936482455553
Article makes very provocative statement - that previous exposure doesn't protect against new variant B.1.351 found initially in S africa. But where are data to support this?
This is v important because previous data have suggested that antibody neutralization of B.1.351 is lower for people w/ previous exposure (& absent for ~1/2), & vaccines provide lower but still substantial protection that most thought would protect against disease.
If this trial actually has data showing that previous exposure does NOT protect against symptomatic disease (the endpoint in this study), that would be qualitatively new information, & actual data should be shared asap.
If trial doesn't have data to strongly support this statement it shouldn't say this & @carlzimmer should revise article ASAP to remove this very strong claim.
Novavax released a presentation document but info there is also very vague (no data!):
https://ir.novavax.com/static-files/e8c12211-6544-4106-b8fb-2b74a9a01265
h/t @BrianOFahey1
This is extremely important - @Novavax please provide actual data on this.
https://ir.novavax.com/static-files/e8c12211-6544-4106-b8fb-2b74a9a01265
h/t @BrianOFahey1
This is extremely important - @Novavax please provide actual data on this.